Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurol… Read more
Hemogenyx Pharmaceuticals Plc (HOPHF) - Net Assets
Latest net assets as of June 2025: $-750.11K USD
Based on the latest financial reports, Hemogenyx Pharmaceuticals Plc (HOPHF) has net assets worth $-750.11K USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.26 Million) and total liabilities ($5.01 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-750.11K |
| % of Total Assets | -17.62% |
| Annual Growth Rate | 30.48% |
| 5-Year Change | -2.53% |
| 10-Year Change | N/A |
| Growth Volatility | 434.38 |
Hemogenyx Pharmaceuticals Plc - Net Assets Trend (2015–2024)
This chart illustrates how Hemogenyx Pharmaceuticals Plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hemogenyx Pharmaceuticals Plc (2015–2024)
The table below shows the annual net assets of Hemogenyx Pharmaceuticals Plc from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $853.49K | -69.31% |
| 2023-12-31 | $2.78 Million | -14.26% |
| 2022-12-31 | $3.24 Million | -60.29% |
| 2021-12-31 | $8.17 Million | +832.71% |
| 2020-12-31 | $875.68K | +350.89% |
| 2019-12-31 | $-349.04K | -136.39% |
| 2018-12-31 | $959.17K | -55.01% |
| 2017-12-31 | $2.13 Million | +135.90% |
| 2016-12-31 | $903.71K | +1061.28% |
| 2015-12-31 | $77.82K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hemogenyx Pharmaceuticals Plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2941764500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $35.05K | 3.90% |
| Other Comprehensive Income | $8.90 Million | 991.39% |
| Other Components | $21.39 Million | 2383.09% |
| Total Equity | $897.51K | 100.00% |
Hemogenyx Pharmaceuticals Plc Competitors by Market Cap
The table below lists competitors of Hemogenyx Pharmaceuticals Plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
High Sierra Technologies Inc
PINK:HSTI
|
$4.48 Million |
|
Vastland Indonesia
JK:VAST
|
$4.49 Million |
|
Humpuss Intermoda Transportasi
JK:HITS
|
$4.49 Million |
|
PMHS
PINK:PMHS
|
$4.49 Million |
|
Creative Medical Technology Holdings Inc
NASDAQ:CELZ
|
$4.48 Million |
|
CHRISTIAN DIOR - Dusseldorf Stock Exchang
DU:DIO
|
$4.48 Million |
|
Bakhu Holdings Corp
PINK:BKUH
|
$4.48 Million |
|
Photon Energy N.V.
WAR:PEN
|
$4.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hemogenyx Pharmaceuticals Plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,818,729 to 897,514, a change of -1,921,215 (-68.2%).
- Net loss of 5,619,181 reduced equity.
- New share issuances of 3,712,490 increased equity.
- Other comprehensive income increased equity by 13,968,591.
- Other factors decreased equity by 13,983,115.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.62 Million | -626.08% |
| Share Issuances | $3.71 Million | +413.64% |
| Other Comprehensive Income | $13.97 Million | +1556.36% |
| Other Changes | $-13.98 Million | -1557.98% |
| Total Change | $- | -68.16% |
Book Value vs Market Value Analysis
This analysis compares Hemogenyx Pharmaceuticals Plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.56x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 1840.29x to 4.56x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $0.00 | $1.24 | x |
| 2015-12-31 | $0.12 | $1.24 | x |
| 2016-12-31 | $2490.10 | $1.24 | x |
| 2017-12-31 | $3276.35 | $1.24 | x |
| 2018-12-31 | $1065.37 | $1.24 | x |
| 2019-12-31 | $-384.25 | $1.24 | x |
| 2020-12-31 | $858.99 | $1.24 | x |
| 2021-12-31 | $4233.76 | $1.24 | x |
| 2022-12-31 | $1337.25 | $1.24 | x |
| 2023-12-31 | $998.54 | $1.24 | x |
| 2024-12-31 | $0.27 | $1.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hemogenyx Pharmaceuticals Plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -626.08%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 4.69x
- Recent ROE (-626.08%) is below the historical average (-146.63%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -14.34% | 0.00% | 0.00x | 1.00x | $-10.64K |
| 2015 | -232.43% | -2642.29% | 0.02x | 4.17x | $-188.66K |
| 2016 | -57.53% | 0.00% | 0.00x | 1.16x | $-610.27K |
| 2017 | -110.78% | 0.00% | 0.00x | 1.12x | $-2.57 Million |
| 2018 | -154.04% | 0.00% | 0.00x | 2.40x | $-1.57 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.42 Million |
| 2020 | -233.74% | 0.00% | 0.00x | 2.99x | $-2.17 Million |
| 2021 | -62.25% | 0.00% | 0.00x | 1.04x | $-5.92 Million |
| 2022 | -121.49% | 0.00% | 0.00x | 2.17x | $-4.31 Million |
| 2023 | -0.24% | 0.00% | 0.00x | 2.17x | $-288.56K |
| 2024 | -626.08% | 0.00% | 0.00x | 4.69x | $-5.71 Million |
Industry Comparison
This section compares Hemogenyx Pharmaceuticals Plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hemogenyx Pharmaceuticals Plc (HOPHF) | $-750.11K | -14.34% | N/A | $4.48 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |